Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Total Payout Ratio : 1.80 (As of Apr. 13, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Great Novel Therapeutics Biotech & Medicals's current Total Payout Ratio is 1.80.

Great Novel Therapeutics Biotech & Medicals Total Payout Ratio Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Total Payout Ratio Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

2.67

3.35

3.65

5.04

1.80

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Payout Ratio	Get a 7-Day Free Trial							-	8.57	0.12	3.01	0.05

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Great Novel Therapeutics Biotech & Medicals Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	188.839	+	0)	/	-104.924
	=	1.80

Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	2.22	+	0)	/	-42.965
	=	0.05

Great Novel Therapeutics Biotech & Medicals Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals Headlines

No Headlines